Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MCBC vs Bu/Cy Conditioning for Refractory/Relapsed AML
NCT06133556Phase 2Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Nov 2023
- Primary completion
- Oct 2028
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of melphalan, cladribine in acute myeloid leukemia (AML), sponsored by Institute of Hematology and Blood Diseases Hospital. Planned start Nov 2023; status: not yet recruiting.
02
Drugs
melphalancladribine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06133556.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06133556.